0001808805FALSE00018088052024-06-132024-06-13



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2024
NAUTILUS BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39434
98-1541723
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

2701 Eastlake Avenue East
Seattle, Washington
(Address of principal executive offices)
98102
(Zip code)
(206) 333-2001
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareNAUTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 5.07.    Submission of Matters to a Vote of Security Holders.
Nautilus Biotechnology, Inc. (the “Company”) held its 2024 annual meeting of stockholders on June 13, 2024 (the “Annual Meeting”). Of the 125,265,015 shares of the Company’s common stock outstanding as of the record date of April 16, 2024, 105,300,784 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
1.Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified:

NomineeVotes ForVotes WithheldBroker Non-Votes
Melissa Epperly92,055,005674,20612,571,573
Matthew L. Posard90,642,6592,086,55212,571,573
Karen Akinsanya89,933,9482,795,26312,571,573

2.Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:

Votes ForVotes AgainstAbstentions
105,058,709172,88769,188




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 13, 2024
NAUTILUS BIOTECHNOLOGY, INC.
By:/s/ Sujal Patel
Name:Sujal Patel
Title:Chief Executive Officer


v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 13, 2024
Entity Registrant Name NAUTILUS BIOTECHNOLOGY, INC.
City Area Code 206
Local Phone Number 333-2001
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001808805
Amendment Flag false
Trading Symbol NAUT
Security Exchange Name NASDAQ
Entity Address, Address Line One 2701 Eastlake Avenue East
Entity Incorporation, State or Country Code DE
Entity Address, Postal Zip Code 98102
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Tax Identification Number 98-1541723
Entity File Number 001-39434
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Nautilus Biotechnology Charts.
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Nautilus Biotechnology Charts.